Panel Discussions of Practical Considerations of Futility Analysis
*Keaven Anderson, Merck & Company  *Susan Ellenberg, University of Pennsylvania  *Scott Evans, Harvard  *John Lawrence, FDA  *Benjamin Trzaskoma, Genentech  *Jialu Zhang, FDA 


This session will consist of two 20-minute oral presentations, one from industry and one from the FDA, followed by a 35-minute panel discussion with representations from industry, FDA, academia and DMCs. The focus is to discuss the challenges and needs from different perspectives and seek better ways to collaborate in the future regarding the design, implementation, and trial integrity of interim analyses and futility analyses.